XML 80 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)
In Thousands, unless otherwise specified
6 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Cash flows from operating activities:    
Net income (loss) $ (9,354) $ 688
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities    
Goodwill impairment loss 4,462 0
Write-down of capitalized software development costs 2,174 0
Depreciation 299 275
Amortization of definite-lived intangible assets 104 156
Capitalized software amortization 478 368
Amortization of deferred financing costs 6 6
Change in fair value of contingent consideration 173 143
Stock-based compensation expense 438 447
Equity (gain) loss on investment in GSE-UNIS Simulation Technology Co. Ltd. 96 (134)
(Gain) loss on derivative instruments 143 (16)
Changes in assets and liabilities:    
Contract receivables 2,786 (5,865)
Prepaid expenses and other assets 215 1,323
Accounts payable, accrued compensation and accrued expenses (562) (204)
Billings in excess of revenue earned 716 (838)
Accrued warranty reserves (329) 163
Other liabilities (86) (303)
Net cash provided by (used in) operating activities 1,759 (3,791)
Cash flows from investing activities:    
Capital expenditures (142) (779)
Capitalized software development costs (995) (608)
Investment in GSE-UNIS Simulation Technology Co. Ltd. 0 (469)
Restrictions of cash as collateral under letters of credit (228) (1,734)
Releases of cash as collateral under letters of credit 0 315
Net cash used in investing activities (1,365) (3,275)
Cash flows from financing activities:    
Proceeds from issuance of common stock 44 221
Payments of the liability-classified contingent consideration arrangements (1,188) (806)
Treasury stock purchases (368) (303)
Net cash used in financing activities (1,512) (888)
Effect of exchange rate changes on cash (177) (106)
Net decrease in cash and cash equivalents (1,295) (8,060)
Cash and cash equivalents at beginning of year 22,386 20,326
Cash and cash equivalents at end of period $ 21,091 $ 12,266